[
    [
        {
            "time": "",
            "original_text": "医美细分Ⅰ：再生元年的针剂趋势",
            "features": {
                "keywords": [
                    "医美",
                    "再生元",
                    "针剂",
                    "趋势"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "美容"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医美细分Ⅰ：再生元年的针剂趋势",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "华东医药复方降糖药二甲双胍恩格列净获批 原研药首次迎来对手",
            "features": {
                "keywords": [
                    "华东医药",
                    "复方降糖药",
                    "二甲双胍",
                    "恩格列净",
                    "原研药",
                    "获批"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华东医药复方降糖药二甲双胍恩格列净获批 原研药首次迎来对手",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "速读社丨FDA批准阿尔茨海默病药Aduhelm 恒瑞、阿斯利康等多款重磅药物新适应症即将获批",
            "features": {
                "keywords": [
                    "FDA",
                    "阿尔茨海默病",
                    "Aduhelm",
                    "恒瑞",
                    "阿斯利康",
                    "重磅药物",
                    "新适应症",
                    "获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "速读社丨FDA批准阿尔茨海默病药Aduhelm 恒瑞、阿斯利康等多款重磅药物新适应症即将获批",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]